Ionis Pharmaceuticals (NASDAQ:IONS) earns a $1.5M milestone payment from development partner GlaxoSmithKline (NYSE:GSK) triggered by the latter's initiation of a Phase 1 clinical trial assessing IONIS-HBV-Lrx for the treatment of hepatitis B virus (HBV) infection. The drug candidate incorporates Ionis' Ligand Conjugated Antisense (LICA) technology which increases drug potency by enhancing its delivery to target tissue, in this case, the liver.
Read a little more...Labels: Glaxo, Ionis Pharmaceutical, phase 1